-
The implementation time of the fourth batch of national procurement is confirmed!
Time of Update: 2021-04-24
The list of the fourth batch of nationally organized centralized drug procurement after the selection of Guizhou Province:In addition, 40mg of pantoprazole sodium for injection will be implemented according to the results of the five provinces and cities, and the national election results will be implemented the following year.
-
Increase the black frame warning!
Time of Update: 2021-04-24
Since parenteral administration of aminoglycoside drugs has ototoxicity and nephrotoxicity, and the safety of treatment for more than 14 days has not been determined, patients receiving such drugs should be closely clinically observed.
-
Jointown employee representative supervisor Chen Li resigns
Time of Update: 2021-04-24
On April 7, Jointown announced that on April 5, the board of supervisors received a written resignation report from the company’s employee representative supervisor Chen Li.
Chen Li applied for resignation from the company’s employee representative supervisor due to personal family reasons.
-
Merck's K drug is approved for new indications in the United States and Europe, Ogalon acquires Alydia
Time of Update: 2021-04-24
"K medicine" hits a wall in the United States"K medicine" hits a wall in the United StatesA few days ago, the US Food and Drug Administration (FDA) issued a complete response letter (CRL) to Merck for the use of Keytruda in the treatment of high-risk early triple-negative breast cancer (TNBC) for supplementary biological license applications (sBLA).
-
Guangshengtang: Innovative hepatitis B treatment drug GST-HG141 was approved for phase Ib clinical trials
Time of Update: 2021-04-24
On April 2nd, Guangshengtang announced that it has recently obtained the review opinion on the phase Ib clinical trial and research of the innovative hepatitis B treatment drug GST-HG141 issued by the
-
Bairen Medical: Innovative product "outflow tract single flap patch" was approved for registration
Time of Update: 2021-04-24
On the 12th, Bairen Medical announced that recently, after review by the National Medical Products Administration, the company's independent research and development of the outflow tract single flap patch was approved for registration.
-
Parkinson's disease drug research and development is gradually heating up. Who can take the lead in breaking the situation with Ling, Luye, and Kangyuan?
Time of Update: 2021-04-24
1 Typical flexion posture of Parkinson's disease(Reference: Handbook of Clinical Neurology, History of Parkinson's disease)02 Pathological Mechanism Research02 Pathological Mechanism ResearchThe main pathological characteristics of PD patients are the damage of dopaminergic neurons in the substantia nigra compact area and the decrease of striatal dopamine content, which in turn causes the weakening of the dopamine innervation function of the substantia nigra-striatal pathway, and the relative cholinergic nerve function Enhancement, the patient has symptoms such as motor dysfunction.
-
When will triple-negative breast cancer produce landmark treatments?
Time of Update: 2021-04-24
In the PrECOG0105 clinical trial, gemcitabine combined with carboplatin and Iniparib (PARP inhibitor) in the treatment of TNBC and BRCA1/2 mutation-related breast cancers showed a pCR rate of 36% and confirmed the predictive function of HRD on the pCR rate of neoadjuvant chemotherapy.
-
Foreign media: European Medicines Agency believes that AstraZeneca vaccine and thrombosis have potential link
Time of Update: 2021-04-24
According to Bloomberg news on April 6, according to the Italian newspaper Il Messaggero, the European Medicines Agency (EMA) believes that AstraZeneca vaccine is potentially linked to blood clots.
-
Pien Tze Huang chairman Liu Jianshun resigns after retirement
Time of Update: 2021-04-24
On April 8, Pien Tze Huang issued an announcement stating that the board of directors had recently received a written resignation report from Chairman Liu Jianshun. Due to personal health reasons, Liu
-
Yahong Pharmaceutical Appoints Dr. Tielin Wang as Senior Vice President of New Drug Discovery
Time of Update: 2021-04-24
Wang Tielin as the Senior Vice President of New Drug Discovery.
Pan Ke. It is understood that Wang Tielin once held the position of vice president at Ruizhi Chemical, responsible for joint research and development projects with a number of large multinational pharmaceutical companies; before returning to China, Dr.
-
Livzon Pharmaceutical's triptorelin pamoate microspheres for injection received clinical approval
Time of Update: 2021-04-24
On April 7th, Livzon Pharmaceutical issued an announcement stating that the company and its wholly-owned subsidiary Livzon Microspheres have recently received the approval of triptorelin pamoate microspheres for injection from the State Food and Drug Administration.
-
China Resources Shuanghe Finasteride Tablets (1mg) were approved for production
Time of Update: 2021-04-24
According to the information on the bidding information of Meinenet's drug in the domestic market, it has been approved in mainland China.
There are 7 manufacturers of finasteride tablets (1mg) on the market.
-
Mycophenolate sodium enteric-coated tablets, a subsidiary of Hengrui Pharmaceuticals, was approved for listing
Time of Update: 2021-04-24
On April 6, Hengrui Medicine issued an announcement stating that its subsidiary Chengdu Shengdi had recently received the "Drug Registration Certificate" for mycophenolate sodium enteric-coated tablets approved and issued by the State Food and Drug Administration.
-
CStone's KIT/PDGFRA mutant kinase inhibitor avatinib was approved in China
Time of Update: 2021-04-24
Today, China’s National Food and Drug Administration (NMPA) drug approval certificate pending information shows that the KIT and PDGFRA mutant kinase inhibitor avapritinib (previously used Chinese name: apotinib) declared by CStone Pharmaceuticals is already available.
-
Sage and Bojian SAGE-324 Phase II tremor test reached the primary endpoint
Time of Update: 2021-04-23
The results of the test showed that in the KINETIC trial (n=67), compared with placebo, patients received the GABAA receptor positive modulator SAGE-324 for 29 days after treatment, the basic tremor rating scale (TETRAS) performance subscale item 4 In the upper extremity tremor score, the primary endpoint of statistically significant reduction was reached (p=0.
-
Panlong Pharmaceutical cancels its wholly-owned subsidiary
Time of Update: 2021-04-23
According to the 2020 annual performance report of Panlong Group, during the reporting period, the company achieved operating income of 670,058,900 yuan, an increase of 9.
73% over the same period of the previous year; realized operating profit of 90,465,200 yuan, an increase of 4.
-
The fifth batch of national procurement reports: 60 varieties are involved, more than half of the injections!
Time of Update: 2021-04-23
Medical Network, April 16 News On April 15, the "Notice on Reporting the Purchasing Data of the Fifth Batch of National Organizations for Centralized Procurement of Drugs" circulated in the industry, which means that the fifth batch of national procurement officially kicked off.
-
The state's multi-sectoral joint "bright sword" to unreasonable medical inspections!
Time of Update: 2021-04-23
The actions specifically include five key contents: The first is to control the conduct of medical inspections in violation of laws and regulations.
The actions specifically include five key contents: The first is to control the conduct of medical inspections in violation of laws and regulations.
-
The difference between Liuwei Dihuang Wan and Zhibai Dihuang Wan
Time of Update: 2021-04-23
So, what is the difference between Liuwei Dihuang Wan and Zhibai Dihuang Wan?Although both drugs belong to the traditional classic prescriptions for nourishing yin and tonifying the kidney, there are differences in clinical application due to the difference in the ingredients of the drugs.
